Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Biocon Limited ( (IN:BIOCON) ) is now available.
Biocon Biologics has been recognized as an Asia IP Elite for 2025 by Intellectual Asset Management (IAM), marking the ninth consecutive year of this accolade. This recognition highlights the company’s strong intellectual property strategy and its role in expanding access to affordable therapies, reinforcing its position as a leader in the global biosimilars market.
More about Biocon Limited
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a global biosimilars company focused on transforming healthcare by providing affordable access to high-quality biosimilars. The company operates in over 120 countries, leveraging advanced science and technology to lower the costs of biological therapeutics and improve healthcare outcomes. It has commercialized 10 biosimilars and has a pipeline of 20 assets across various therapeutic areas.
Average Trading Volume: 157,109
Technical Sentiment Signal: Strong Buy
Current Market Cap: 516B INR
For an in-depth examination of BIOCON stock, go to TipRanks’ Overview page.